• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Theravance Biopharma, Inc. Announces Appointment of Jim Kelly, Managing Director at Weiss Asset Management, to Board of Directors

    4/11/23 4:05:00 PM ET
    $TBPH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TBPH alert in real time by email

    DUBLIN, April 11, 2023 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced the appointment of Jim Kelly, Managing Director at Weiss Asset Management, the Company's second largest shareholder, to its Board of Directors. With the appointment of Mr. Kelly, four new directors have joined the Company's Board of Directors since 2018 as part of its ongoing board refreshment process.

    Theravance Biopharma Logo (PRNewsfoto/Theravance Biopharma, Inc.)

    "We are pleased to welcome Jim Kelly to the Theravance Board of Directors. Weiss Asset Management has been one of our largest shareholders since 2021, and Jim has extensive investment experience as well as a thorough understanding of our industry, our Company and the communities we serve," said Rick E Winningham, Chairman and CEO. "We believe Jim's perspective, knowledge of the capital markets and deep financial acumen are highly valuable to, and further strengthen, our Board as we continue to execute on our strategy and seek to maximize value for all of our shareholders." 

    "I am excited to join the Board of Directors of Theravance Biopharma," said Mr. Kelly. "I am personally devoted to the success of this Company, and I am committed to leveraging my experience to support the Company in achieving its full potential. I look forward to working collaboratively with my fellow Board members and management to drive continued success for the Company and deliver short- and long-term growth and shareholder returns." 

    Mr. Kelly is currently a Managing Director of Weiss Asset Management and a member of the firm's Investment Committee. Mr. Kelly has nearly twenty years of experience as a professional investor in the public and private markets and a decade of experience investing in healthcare. Prior to joining Weiss Asset Management, Mr. Kelly was an analyst at Farallon Capital Management, Madison Dearborn Partners and Lehman Brothers. Founded in 1991 and based in Boston, Weiss Asset Management has approximately $3 billion in assets under management.

    About Theravance Biopharma

    Theravance Biopharma, Inc.'s focus is to deliver Medicines that Make a Difference® in people's lives. In pursuit of its purpose, Theravance Biopharma leverages decades of expertise, which has led to the development of FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Ampreloxetine, its late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension, has the potential to be a first in class therapy effective in treating a constellation of cardinal symptoms in multiple symptom atrophy patients. The Company is committed to creating/driving shareholder value.

    For more information, please visit www.theravance.com.

    THERAVANCE BIOPHARMA®, THERAVANCE® and the Cross/Star logo are registered trademarks of the Theravance Biopharma group of companies (in the U.S. and certain other countries).

    YUPELRI® is a registered trademark of Mylan Specialty L.P., a Viatris company. Trademarks, trade names or service marks of other companies appearing in this press release are the property of their respective owners.

    Forward-Looking Statements

    This press release contains certain "forward-looking" statements as that term is defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things, statements relating to goals, plans, objectives, expectations and future events. Theravance Biopharma intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Examples of such statements include statements relating to execution on the Company's strategy, the maximization of shareholder value, and the Company's goals, designs, strategies, plans and objectives. These statements are based on the current estimates and assumptions of the management of Theravance Biopharma as of the date of this press release and are subject to risks, uncertainties, changes in circumstances, assumptions and other factors that may cause the actual results of Theravance Biopharma to be materially different from those reflected in the forward-looking statements. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include, among others, risks related to delays or difficulties in commencing, enrolling or completing clinical studies; the potential that results from clinical or non-clinical studies indicate the Company's product candidates or product are unsafe, ineffective or not differentiated; risks of decisions from regulatory authorities that are unfavorable to the Company; dependence on third parties to conduct clinical studies; delays or failure to achieve and maintain regulatory approvals for product candidates; risks of collaborating with or relying on third parties to discover, develop, manufacture and commercialize products; risks associated with establishing and maintaining sales, marketing and distribution capabilities with appropriate technical expertise and supporting infrastructure; ability to retain key personnel; the ability of the Company to protect and to enforce its intellectual property rights; volatility and fluctuations in the trading price and volume of the Company's shares; and general economic and market conditions. Other risks affecting Theravance Biopharma are in the Company's Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on March 1, 2023, and other periodic reports filed with the SEC. In addition to the risks described above and in Theravance Biopharma's filings with the SEC, other unknown or unpredictable factors also could affect Theravance Biopharma's results. No forward-looking statements can be guaranteed, and actual results may differ materially from such statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Theravance Biopharma assumes no obligation to update its forward-looking statements on account of new information, future events or otherwise, except as required by law.

    Important Additional Information and Where to Find It

    Theravance Biopharma filed proxy materials with the SEC in connection with the solicitation of proxies for the Company's 2023 Annual General Meeting of Shareholders (the "Annual Meeting"). On March 28, 2023, Theravance Biopharma filed a definitive proxy statement (the "Proxy Statement") together with a WHITE proxy card. SHAREHOLDERS ARE URGED TO READ THE PROXY STATEMENT (INCLUDING ANY AMENDMENTS OR SUPPLEMENTS THERETO) AND ANY OTHER RELEVANT DOCUMENTS THAT THE COMPANY WILL FILE WITH THE SEC CAREFULLY AND IN THEIR ENTIRETY AS THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Shareholders will be able to obtain, free of charge, copies of the Proxy Statement, any amendments or supplements thereto and any other documents (including the WHITE proxy card) filed by the Company with the SEC in connection with the Annual Meeting at the SEC's website (http://www.sec.gov) or at the Company's website https://investor.theravance.com/.

    Certain Information Regarding Participants

    The Company, its directors and certain of its executive officers and other employees may be deemed to be participants in the solicitation of proxies from shareholders in connection with the Annual Meeting. Additional information regarding the identity of these potential participants (none of whom, other than Rick Winningham, own in excess of one percent (1%) of the Company's shares) and their direct or indirect interests, by security holdings or otherwise, have been set forth in the Proxy Statement and other materials filed and to be filed with the SEC in connection with the Annual Meeting. To the extent holdings of the Company's securities by such potential participants (or the identity of such participants) have changed since the information printed in the Proxy Statement, such information has been or will be reflected on Statements of Change in Ownership on Forms 3 and 4 filed with the SEC. You may obtain free copies of these documents using the sources indicated above.

    Contact:

    [email protected]

    650-808-4045

     

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/theravance-biopharma-inc-announces-appointment-of-jim-kelly-managing-director-at-weiss-asset-management-to-board-of-directors-301794838.html

    SOURCE Theravance Biopharma, Inc.

    Get the next $TBPH alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $TBPH

    DatePrice TargetRatingAnalyst
    8/6/2024$15.00 → $10.00Outperform → Market Perform
    Leerink Partners
    4/12/2024$21.00Buy
    BTIG Research
    1/8/2024Outperform → In-line
    Evercore ISI
    5/23/2022$12.00Outperform
    SVB Leerink
    3/2/2022$10.00 → $11.00Underweight
    Morgan Stanley
    2/24/2022$8.00 → $12.00Buy
    HC Wainwright & Co.
    11/5/2021$7.00 → $12.00Underweight → Neutral
    JP Morgan
    9/16/2021$14.00 → $10.00Underweight
    Morgan Stanley
    More analyst ratings

    $TBPH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Theravance Biopharma downgraded by Leerink Partners with a new price target

      Leerink Partners downgraded Theravance Biopharma from Outperform to Market Perform and set a new price target of $10.00 from $15.00 previously

      8/6/24 8:00:45 AM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • BTIG Research initiated coverage on Theravance Biopharma with a new price target

      BTIG Research initiated coverage of Theravance Biopharma with a rating of Buy and set a new price target of $21.00

      4/12/24 7:40:50 AM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Theravance Biopharma downgraded by Evercore ISI

      Evercore ISI downgraded Theravance Biopharma from Outperform to In-line

      1/8/24 8:38:16 AM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TBPH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CHIEF EXECUTIVE OFFICER Winningham Rick E gifted 9,600 units of Ordinary Shares and received a gift of 9,600 units of Ordinary Shares, decreasing direct ownership by 0.54% to 1,753,180 units (SEC Form 4)

      4 - Theravance Biopharma, Inc. (0001583107) (Issuer)

      6/17/25 6:16:33 PM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SVP, COMM & MEDICAL AFFAIRS Farnum Rhonda sold $264,000 worth of Ordinary Shares (24,000 units at $11.00), decreasing direct ownership by 7% to 336,918 units (SEC Form 4)

      4 - Theravance Biopharma, Inc. (0001583107) (Issuer)

      6/4/25 6:04:21 PM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CHIEF EXECUTIVE OFFICER Winningham Rick E covered exercise/tax liability with 15,364 units of Ordinary Shares, decreasing direct ownership by 0.86% to 1,762,780 units (SEC Form 4)

      4 - Theravance Biopharma, Inc. (0001583107) (Issuer)

      5/22/25 6:44:56 PM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $TBPH
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Theravance Biopharma, Inc. Sells Remaining Royalty Interest in Trelegy Ellipta to GSK for $225 Million

      Definitive agreement to result in one-time $225 million cash payment Theravance Biopharma retains rights to up to $150 million in milestones from Royalty Pharma on Trelegy Ellipta net sales in 2025 and 2026, requiring minimal to no growth over 2024 actuals to be achieved$225 million from royalty transaction announced today, in addition to the $1.1 billion upfront received in 2022, and up to $200 million in milestones (of which $50 million was received in 2025), brings total potential lifetime value from Trelegy Ellipta monetization efforts to $1.525 billionFirst outcome from Strategic Review Committee's ongoing efforts to maximize shareholder value; Board remains committed to returning exces

      6/2/25 6:00:00 AM ET
      $GSK
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Theravance Biopharma to Participate in an Upcoming Investor Conference

      DUBLIN, May 13, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. (NASDAQ:TBPH) will participate in a Fireside Chat at the H.C. Wainwright 3rd Annual BioConnect Investor Conference in New York City at NASDAQ Tuesday, May 20 at 10:30 AM EDT (7:30 AM PDT / 3:30 PM IST) and will be hosting in-person meetings with the investment community at the conference. A webcast of the event may be accessed by visiting Theravance.com, under the Investors section, Events and Presentations. A replay of the webcast will be archived on the Company's website for 30 days. About Theravance Biopharma

      5/13/25 6:00:00 AM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Theravance Biopharma Announces Ampreloxetine Presentations at the International MSA Congress

      DUBLIN, May 9, 2025 /PRNewswire/ -- Theravance Biopharma, Inc. ("Theravance Biopharma" or the "Company") (NASDAQ:TBPH) today announced presentation of analyses of its previous Phase 3 program evaluating ampreloxetine, an investigational medicine for the treatment of symptomatic neurogenic orthostatic hypotension (nOH) at the International MSA Congress, taking place May 9-11 in Boston, Massachusetts. A subgroup analysis selected as a platform presentation focused on patients with Multiple System Atrophy (MSA) in the REDWOOD 0170 study (NCT03829657), an international phase 3, pl

      5/9/25 12:00:00 PM ET
      $TBPH
      Biotechnology: Pharmaceutical Preparations
      Health Care